Gedeon Richter Spends Most On Biosimilar R&D

Multiple Candidates In Clinical Phase Including Denosumab

 
• By Dean Rudge
Clinical_Trial_Globe
Biosimilar Prolia/Xgeva and Actemra/RoActemra candidates are entering the clinical phase • Source: Shutterstock

More from Biosimilars

More from Products